GlobalData on MSN6h
AnaptysBio’s atopic dermatitis trial of BTLA agonist misses endpointsAnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...
Columvi combo in DLBCL, while AnaptysBio's ANB032 fails in atopic dermatitis. Essential Pharma gets €1.2B financing deal.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback